Astellas Pharma (OTCMKTS:ALPMY) Issues Quarterly Earnings Results

Astellas Pharma (OTCMKTS:ALPMY) released its quarterly earnings data on Wednesday. The company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.41 by ($0.06), Zacks reports. The company had revenue of $3.98 billion during the quarter, compared to analysts’ expectations of $3.79 billion. Astellas Pharma had a net margin of 16.18% and a return on equity of 26.13%.

Astellas Pharma Stock Performance

Shares of Astellas Pharma stock opened at $16.40 on Friday. The company has a current ratio of 1.20, a quick ratio of 0.93 and a debt-to-equity ratio of 0.16. The stock’s fifty day moving average price is $15.07 and its 200-day moving average price is $14.75. The firm has a market cap of $29.68 billion, a P/E ratio of 9.31 and a beta of 0.06. Astellas Pharma has a 12 month low of $10.91 and a 12 month high of $17.35.

Analysts Set New Price Targets

Separately, Zacks Research lowered Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

About Astellas Pharma

Astellas Pharma Inc is a Japan-based pharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines. Its research and commercial activities focus on areas including oncology, urology, immunology, neuroscience, ophthalmology and rare diseases. The company serves patients and healthcare providers in Japan, North America, Europe and other international markets.

Astellas’ portfolio includes medicines such as Xtandi (enzalutamide) for certain prostate cancers, Xospata (gilteritinib) for acute myeloid leukemia, Prograf (tacrolimus) for transplant-related immunosuppression, and Myrbetri (mirabegron) for overactive bladder.